{"pmid":32337664,"title":"Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia.","text":["Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia.","Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. IL-6 is one of the key cytokines involved in infection-induced cytokine storm. Tocilizumab, which is the IL-6 receptor antagonist, has been approved by the US FDA for the treatment of cytokine release syndrome (CRS), is expected to treat cytokine storm caused by COVID-19 and is now in clinical trials. In this paper, we will elaborate the role of cytokine storm in COVID-19, the mechanism of tocilizumab on cytokine storm and the key points of pharmaceutical care based on the actual clinical application for COVID-19 in our hospital, the latest research reports, clinical trial progress of tocilizumab, drug instruction from the US FDA, and \"Diagnosis and Treatment Plan of Novel Coronavirus Pneumonia (seventh trial edition)\" in China, so as to provide reference for the treatment of COVID-19.","Clin Drug Investig","Zhang, Shengyu","Li, Lei","Shen, Aizong","Chen, Yongwu","Qi, Zhigang","32337664"],"abstract":["Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. IL-6 is one of the key cytokines involved in infection-induced cytokine storm. Tocilizumab, which is the IL-6 receptor antagonist, has been approved by the US FDA for the treatment of cytokine release syndrome (CRS), is expected to treat cytokine storm caused by COVID-19 and is now in clinical trials. In this paper, we will elaborate the role of cytokine storm in COVID-19, the mechanism of tocilizumab on cytokine storm and the key points of pharmaceutical care based on the actual clinical application for COVID-19 in our hospital, the latest research reports, clinical trial progress of tocilizumab, drug instruction from the US FDA, and \"Diagnosis and Treatment Plan of Novel Coronavirus Pneumonia (seventh trial edition)\" in China, so as to provide reference for the treatment of COVID-19."],"journal":"Clin Drug Investig","authors":["Zhang, Shengyu","Li, Lei","Shen, Aizong","Chen, Yongwu","Qi, Zhigang"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337664","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1007/s40261-020-00917-3","locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1665264685460488193,"score":8.574329,"similar":[{"pmid":32234467,"pmcid":"PMC7118634","title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","text":["The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19.","Int J Antimicrob Agents","Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang","32234467"],"abstract":["Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19."],"journal":"Int J Antimicrob Agents","authors":["Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234467","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105954","keywords":["covid-19","cytokine release syndrome","tocilizumab"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab"],"_version_":1664638354264686592,"score":428.00717},{"pmid":32343968,"title":"Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report.","text":["Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report.","Novel coronavirus, COVID-19 emerged late December 2019 in Wuhan, China. Since then, COVID-19 has become a pandemic affecting more than 1.5 million people worldwide. Patients with COVID-19 have a wide spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal correlate, secondary hemophagocytic lymphohistiocytosis (sHLH). Anti-cytokine therapy such as tocilizumab, an interleukin-6 (IL-6) receptor antagonist, is a potential treatment for COVID-19, however data regarding the efficacy of this anti-IL-6 therapy is currently lacking. We report two cases of patients diagnosed with COVID-19 complicated by CRS treated with tocilizumab. Both patients progressed to sHLH despite treatment with tocilizumab and one developed viral myocarditis challenging the safety and clinical utility of tocilizumab in the treatment of COVID-19-induced CRS. These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process.","Chest","Radbel, Jared","Narayanan, Navaneeth","Bhatt, Pinki J","32343968"],"abstract":["Novel coronavirus, COVID-19 emerged late December 2019 in Wuhan, China. Since then, COVID-19 has become a pandemic affecting more than 1.5 million people worldwide. Patients with COVID-19 have a wide spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal correlate, secondary hemophagocytic lymphohistiocytosis (sHLH). Anti-cytokine therapy such as tocilizumab, an interleukin-6 (IL-6) receptor antagonist, is a potential treatment for COVID-19, however data regarding the efficacy of this anti-IL-6 therapy is currently lacking. We report two cases of patients diagnosed with COVID-19 complicated by CRS treated with tocilizumab. Both patients progressed to sHLH despite treatment with tocilizumab and one developed viral myocarditis challenging the safety and clinical utility of tocilizumab in the treatment of COVID-19-induced CRS. These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process."],"journal":"Chest","authors":["Radbel, Jared","Narayanan, Navaneeth","Bhatt, Pinki J"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343968","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.chest.2020.04.024","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1665351883897700352,"score":381.2133},{"pmid":32290839,"pmcid":"PMC7154566","title":"Why tocilizumab could be an effective treatment for severe COVID-19?","text":["Why tocilizumab could be an effective treatment for severe COVID-19?","A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.","J Transl Med","Fu, Binqing","Xu, Xiaoling","Wei, Haiming","32290839"],"abstract":["A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality."],"journal":"J Transl Med","authors":["Fu, Binqing","Xu, Xiaoling","Wei, Haiming"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32290839","week":"202016|Apr 13 - Apr 19","doi":"10.1186/s12967-020-02339-3","keywords":["acute respiratory distress syndrome (ards)","covid-19","il-6","inflammatory storm","sars-cov-2","tocilizumab"],"link_comment_in":"32290847","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["tocilizumab"],"_version_":1664636192640991234,"score":353.0412},{"pmid":32291137,"pmcid":"PMC7151347","title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","text":["Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. However, the efficacy of corticosteroids, commonly utilized antiinflammatory agents, to treat COVID-19-induced CRS is controversial. There is an urgent need for novel therapies to treat COVID-19-induced CRS. Here, we discuss the pathogenesis of severe acute respiratory syndrome (SARS)-induced CRS, compare the CRS in COVID-19 with that in SARS and Middle East respiratory syndrome (MERS), and summarize the existing therapies for CRS. We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS and discuss several factors that should be taken into consideration for its clinical application.","J Autoimmun","Liu, Bingwen","Li, Min","Zhou, Zhiguang","Guan, Xuan","Xiang, Yufei","32291137"],"abstract":["The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. However, the efficacy of corticosteroids, commonly utilized antiinflammatory agents, to treat COVID-19-induced CRS is controversial. There is an urgent need for novel therapies to treat COVID-19-induced CRS. Here, we discuss the pathogenesis of severe acute respiratory syndrome (SARS)-induced CRS, compare the CRS in COVID-19 with that in SARS and Middle East respiratory syndrome (MERS), and summarize the existing therapies for CRS. We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS and discuss several factors that should be taken into consideration for its clinical application."],"journal":"J Autoimmun","authors":["Liu, Bingwen","Li, Min","Zhou, Zhiguang","Guan, Xuan","Xiang, Yufei"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291137","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaut.2020.102452","keywords":["coronavirus disease 2019","cytokine release syndrome","interleukin-6","tocilizumab"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664636192545570817,"score":330.882},{"pmid":32283152,"title":"The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.","text":["The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.","Cytokine storm is an excessive immune response to external stimuli. The pathogenesis of the cytokine storm is complex. The disease progresses rapidly, and the mortality is high. Certain evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, the severe deterioration of some patients has been closely related to the cytokine storm in their bodies. This article reviews the occurrence mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment.","J Infect","Ye, Qing","Wang, Bili","Mao, Jianhua","32283152"],"abstract":["Cytokine storm is an excessive immune response to external stimuli. The pathogenesis of the cytokine storm is complex. The disease progresses rapidly, and the mortality is high. Certain evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, the severe deterioration of some patients has been closely related to the cytokine storm in their bodies. This article reviews the occurrence mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment."],"journal":"J Infect","authors":["Ye, Qing","Wang, Bili","Mao, Jianhua"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283152","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jinf.2020.03.037","keywords":["2019-ncov","coronavirus","cytokine storm","immunomodulation","sars-cov-2"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Cytokine"],"_version_":1664636703978029057,"score":306.4124}]}